Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
CONTACT
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Willingness to undergo a procedure to obtain tumor tissue (e.g. biopsy) and blood draw
Diagnosis of HER2+, HR+ (for cohort R1) or triple negative breast cancer (for cohort T1) as per local assessment
Availability of an archival tumor tissue (most recent pre-treatment tumor tissue is preferred)
Unequivocally growing tumor lesion (progressive lesion) that is accessible for resection, excision or core needle biopsy
Discontinuation of prior anti-cancer treatment outlined below should not be longer than 4 weeks from participation in this study
Participant had undergone regular monitoring for disease progression as per local practice (preferably every 3-6 months) while on most recent breast cancer therapy
Accessible tumor lesion that newly appeared or a lesion that started to regrow while the participant was at least 6 months on therapy
Accessible tumor lesion that continued to increase in size or a newly appearing lesion (as confirmed by routine tumor assessment) while treated for at least 4 weeks but less than 6 months on therapy
You may not be if
Any risks factors that increase the risk of complications associated with the procedure to obtain tumor tissue (e.g. bleeding disorders)
Any serious medical condition or abnormality in clinical laboratory tests that precludes an individual's safe participation in and completion of the study
Participant has started treatment with subsequent anti-cancer therapy
Participants whose progressive tumor lesion that is targeted for biopsy/resection is in the bone
Discontinuation of treatment was due to a reason other than disease progression
Clareo Health | A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
